The TP53 mutation rate is <10% of cases of de novo AML [4]; however, inactivation of wild-type p53 occurs in many patients with AML by alternative mechanisms, including overexpression of MDM2, in order to allow proliferation and leukemogenesis. The gene discussed is TP53; the disease is acute myeloid leukemia.